<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00944346</url>
  </required_header>
  <id_info>
    <org_study_id>40484</org_study_id>
    <nct_id>NCT00944346</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Bioequivalence of a Test Tablet Formulation of Metformin HCl (1000 mg), Compared to an Equivalent Dose of a Commercially Available Reference Drug Product (Glucophage®, Bristol-Myers Squibb Company) in Fed, Healthy, Adult Subjects</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Torrent Pharmaceuticals Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Torrent Pharmaceuticals Limited</source>
  <brief_summary>
    <textblock>
      -  Objective:&#xD;
&#xD;
             -  A Randomized, Two-Way Crossover, Single-Dose, Open-Label Study to Evaluate the&#xD;
                Bioequivalence of a Test Tablet Formulation of Metformin HCl (1000 mg), Compared to&#xD;
                an Equivalent Dose of a Commercially Available Reference Drug Product (Glucophage®,&#xD;
                Bristol-Myers Squibb Company) in Fasted, Healthy, Adult Subjects.&#xD;
&#xD;
        -  Study Design:&#xD;
&#xD;
             -  Randomized,single-dose,2-way crossover.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <condition>Healthy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin HCl</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject is at least 18 years old.&#xD;
&#xD;
          -  Subject had no clinically significant abnormal lab values at the screening evaluation.&#xD;
&#xD;
          -  Subject's drugs of abuse, Hepatitis B, Hepatitis C, and HIV screenings were negative&#xD;
             or non-relative.&#xD;
&#xD;
          -  Acceptable screening of ECG.&#xD;
&#xD;
          -  Female subject's pregnancy test at screening is negative.&#xD;
&#xD;
          -  Subject had no evidence of underlying disease at the pre-entry physical examination.&#xD;
&#xD;
          -  Subject has given written consent to participate.&#xD;
&#xD;
          -  Female subject has not received any injectable or implantable contraceptive for a&#xD;
             period of six months preceding this study.&#xD;
&#xD;
          -  Agreed to undergo at least a 14-day pre-dose washout.&#xD;
&#xD;
          -  Beginning two weeks prior to dosing and throughout the study, female subject of&#xD;
             childbearing potential agrees to utilize one of the following methods of&#xD;
             contraception:&#xD;
&#xD;
               1. Condom and topical spermicide&#xD;
&#xD;
               2. Condom and diaphragm&#xD;
&#xD;
               3. Intra-uterine device (I.U.D)&#xD;
&#xD;
               4. Complete abstinence.&#xD;
&#xD;
          -  Agree to abstain from consuming caffeine or alcohol for at least 48 hours. prior to&#xD;
             study and throughout the blood collection periods.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of treatment for alcoholism, substance abuse, or drug abuse with in the past&#xD;
             24 months.&#xD;
&#xD;
          -  History of malignancy, stroke, diabetes, cardiac, renal or liver disease, or other&#xD;
             serious illness.&#xD;
&#xD;
          -  History of GRD, malabsorption syndrome, colon cancer, or chronic colitis, including&#xD;
             Crohn's disease.&#xD;
&#xD;
          -  History of treatment for asthma, hypoxemia, dehydration, sepsis, metabolic acidosis&#xD;
             and congestive heart failure.&#xD;
&#xD;
          -  Subject is pregnant or lactating.&#xD;
&#xD;
          -  History of drug hyper sensitivity.&#xD;
&#xD;
          -  Subject was treated with any investigational drug during the four weeks prior to&#xD;
             initial dosing for the study.&#xD;
&#xD;
          -  Subject smokes more then 15 cigarettes per day or uses tobacco products or currently&#xD;
             uses nicotine products.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Gateway Medical Research, Inc.</name>
      <address>
        <city>St, Charles</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2009</verification_date>
  <study_first_submitted>July 21, 2009</study_first_submitted>
  <study_first_submitted_qc>July 22, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 23, 2009</study_first_posted>
  <last_update_submitted>July 22, 2009</last_update_submitted>
  <last_update_submitted_qc>July 22, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 23, 2009</last_update_posted>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

